Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF A Koski, L Kangasniemi, S Escutenaire, S Pesonen, V Cerullo, I Diaconu, ... Molecular Therapy 18 (10), 1874-1884, 2010 | 265 | 2010 |
Antiviral and antitumor T-cell immunity in patients treated with GM-CSF–coding oncolytic adenovirus A Kanerva, P Nokisalmi, I Diaconu, A Koski, V Cerullo, I Liikanen, ... Clinical Cancer Research 19 (10), 2734-2744, 2013 | 203 | 2013 |
Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus V Cerullo, I Diaconu, L Kangasniemi, M Rajecki, S Escutenaire, A Koski, ... Molecular Therapy 19 (9), 1737-1746, 2011 | 182 | 2011 |
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients I Liikanen, L Ahtiainen, MLM Hirvinen, S Bramante, V Cerullo, ... Molecular Therapy 21 (6), 1212-1223, 2013 | 181 | 2013 |
Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy O Hemminki, S Parviainen, J Juhila, R Turkki, N Linder, J Lundin, ... Oncotarget 6 (6), 4467, 2015 | 79 | 2015 |
Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy O Hemminki, S Parviainen, J Juhila, R Turkki, N Linder, J Lundin, ... Oncotarget 6 (6), 4467, 2015 | 79 | 2015 |
Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans V Cerullo, A Koski, M Vähä-Koskela, A Hemminki Advances in cancer research 115, 265-318, 2012 | 76 | 2012 |
Oncolytic adenovirus based on serotype 3 O Hemminki, G Bauerschmitz, S Hemmi, S Lavilla-Alonso, I Diaconu, ... Cancer gene therapy 18 (4), 288-296, 2011 | 65 | 2011 |
Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM‐CSF: Results in vitro, in rodents and in humans S Bramante, JK Kaufmann, V Veckman, I Liikanen, DM Nettelbeck, ... International journal of cancer 137 (7), 1775-1783, 2015 | 55 | 2015 |
Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy I Liikanen, A Koski, M Merisalo-Soikkeli, O Hemminki, M Oksanen, ... Oncoimmunology 4 (3), e989771, 2015 | 54 | 2015 |
Serotype chimeric oncolytic adenovirus coding for GM‐CSF for treatment of sarcoma in rodents and humans S Bramante, A Koski, A Kipar, I Diaconu, I Liikanen, O Hemminki, ... International Journal of Cancer 135 (3), 720-730, 2014 | 51 | 2014 |
Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells A Koski, M Rajecki, K Guse, A Kanerva, A Ristimäki, S Pesonen, ... The Journal of Gene Medicine: A cross‐disciplinary journal for research on …, 2009 | 48 | 2009 |
Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer A Koski, M Raki, P Nokisalmi, I Liikanen, L Kangasniemi, T Joensuu, ... Molecular Therapy 20 (1), 221-229, 2012 | 39 | 2012 |
ADHD desynchronizes brain activity during watching a distracted multi-talker conversation J Salmi, M Metwaly, J Tohka, K Alho, S Leppämäki, P Tani, A Koski, ... NeuroImage 216, 116352, 2020 | 38 | 2020 |
Predictive and prognostic clinical variables in cancer patients treated with adenoviral oncolytic immunotherapy K Taipale, I Liikanen, A Koski, R Heiskanen, A Kanerva, O Hemminki, ... Molecular Therapy 24 (7), 1323-1332, 2016 | 36 | 2016 |
Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer S Bramante, A Koski, I Liikanen, L Vassilev, M Oksanen, M Siurala, ... Oncoimmunology 5 (2), e1078057, 2016 | 35 | 2016 |
Chronic activation of innate immunity correlates with poor prognosis in cancer patients treated with oncolytic adenovirus K Taipale, I Liikanen, J Juhila, R Turkki, S Tähtinen, M Kankainen, ... Molecular Therapy 24 (1), 175-183, 2016 | 35 | 2016 |
Biodistribution analysis of oncolytic adenoviruses in patient autopsy samples reveals vascular transduction of noninjected tumors and tissues A Koski, S Bramante, A Kipar, M Oksanen, J Juhila, L Vassilev, T Joensuu, ... Molecular Therapy 23 (10), 1641-1652, 2015 | 32 | 2015 |
Aikuisen autismikirjon häiriö L autismin oireet ICD10tautiluoki Duodecim 134, 1493-500, 2018 | 26 | 2018 |
Effects of capsid‐modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer L Kangasniemi, S Parviainen, T Pisto, M Koskinen, M Jokinen, T Kiviluoto, ... International journal of cancer 131 (1), 253-263, 2012 | 21 | 2012 |